Literature DB >> 22689672

Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease.

Mindaugas Andrulis1, Sascha Dietrich, Thomas Longerich, Ronald Koschny, Maria Burian, Annette Schmitt-Gräf, Peter Schirmacher, Anthony D Ho, Peter Dreger, Thomas Luft.   

Abstract

Steroid-refractory graft-versus-host disease causes significant morbidity and mortality after allogeneic stem cell transplantation. The pathomechanism of steroid resistance is currently not understood, but it has been suggested that endothelial cell dysfunction plays a role. Endothelial thrombomodulin was quantified along with histological markers of epithelial damage and cytotoxic T cells in colon biopsies from 51 allografted patients, and retrospectively correlated with response to steroids and survival. Loss of endothelial thrombomodulin was the strongest predictor of response to steroids (P=0.02) and nonrelapse mortality (P=0.01) in multivariate analyses adjusting for T-cell infiltrates, histological grading, vessel density, disease status, donor type, and conditioning therapy. Our data provide evidence that at disease onset, loss of endothelial thrombomodulin expression rather than excessive T-cell infiltration associates with steroid-refractory graft-versus-host disease and mortality. Prospective histological investigations are now warranted to improve diagnosis and prognostication of this core complication of stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689672      PMCID: PMC3487439          DOI: 10.3324/haematol.2011.061051

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

1.  Elevated serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis.

Authors:  M W Boehme; F Autschbach; I Zuna; W A Scherbaum; E Stange; U Raeth; A Sieg; W Stremmel
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

2.  Regression modeling of competing risk using R: an in depth guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

3.  Competing risk analysis using R: an easy guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

4.  Graft-versus-host disease treatment: predictors of survival.

Authors:  John E Levine; Brent Logan; Juan Wu; Amin M Alousi; Vincent Ho; Javier Bolaños-Meade; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-09       Impact factor: 5.742

5.  Is the loss of endothelial thrombomodulin involved in the mechanism of chronicity in late radiation enteropathy?

Authors:  K K Richter; L M Fink; B M Hughes; C C Sung; M Hauer-Jensen
Journal:  Radiother Oncol       Date:  1997-07       Impact factor: 6.280

Review 6.  Novel strategies for steroid-refractory acute graft-versus-host disease.

Authors:  Javier Bolaños-Meade; Georgia B Vogelsang
Journal:  Curr Opin Hematol       Date:  2005-01       Impact factor: 3.284

Review 7.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

8.  Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

Authors:  Alois Gratwohl; Martin Stern; Ronald Brand; Jane Apperley; Helen Baldomero; Theo de Witte; Giorgio Dini; Vanderson Rocha; Jakob Passweg; Anna Sureda; André Tichelli; Dietger Niederwieser
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

Review 9.  Vascular endothelium and graft-versus-host disease.

Authors:  Barbara C Biedermann
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

Review 10.  Pathology of graft-versus-host disease in the gastrointestinal tract.

Authors:  Kay Washington; Madan Jagasia
Journal:  Hum Pathol       Date:  2009-07       Impact factor: 3.466

View more
  17 in total

1.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

2.  How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver.

Authors:  George B McDonald
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

Review 3.  New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Adam Nelson; Gregory Wallace; Benjamin L Laskin
Journal:  Transfus Apher Sci       Date:  2016-04-25       Impact factor: 1.764

4.  A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.

Authors:  Haruka Nomoto; Akiyoshi Takami; J Luis Espinoza; Keitaro Matsuo; Shohei Mizuno; Makoto Onizuka; Koichi Kashiwase; Yasuo Morishima; Takahiro Fukuda; Yoshihisa Kodera; Noriko Doki; Koichi Miyamura; Takehiko Mori; Shinji Nakao; Shigeki Ohtake; Eriko Morishita
Journal:  Int J Hematol       Date:  2015-08-06       Impact factor: 2.490

5.  High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy.

Authors:  Sascha Dietrich; Jürgen G Okun; Kathrin Schmidt; Christine S Falk; Andreas H Wagner; Suzan Karamustafa; Aleksandar Radujkovic; Ute Hegenbart; Anthony D Ho; Peter Dreger; Thomas Luft
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

6.  Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Laura F Newell; Todd E DeFor; Corey Cutler; Michael R Verneris; Bruce R Blazar; Jeff S Miller; Joseph H Antin; Alan Howard; Juan Wu; Margaret L MacMillan; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Shernan G Holtan
Journal:  Biol Blood Marrow Transplant       Date:  2019-11-10       Impact factor: 5.742

Review 7.  A risk-adapted approach to acute GVHD treatment: are we there yet?

Authors:  S G Holtan; M L MacMillan
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

8.  The glycome of normal and malignant plasma cells.

Authors:  Thomas M Moehler; Anja Seckinger; Dirk Hose; Mindaugas Andrulis; Jèrôme Moreaux; Thomas Hielscher; Martina Willhauck-Fleckenstein; Anette Merling; Uta Bertsch; Anna Jauch; Hartmut Goldschmidt; Bernard Klein; Reinhard Schwartz-Albiez
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

Review 9.  Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation.

Authors:  Thomas Luft; Peter Dreger; Aleksandar Radujkovic
Journal:  Bone Marrow Transplant       Date:  2021-07-12       Impact factor: 5.483

10.  EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.

Authors:  Thomas Luft; Clemens-Martin Wendtner; Florentina Kosely; Aleksandar Radujkovic; Axel Benner; Felix Korell; Lars Kihm; Matthias F Bauer; Peter Dreger; Uta Merle
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.